HPV vaccine and its recommendations, 2007

Journal of Family Practice

Volumn 56, Issue SUPPL. 2, 2007, Pages

  Zimmerman, Richard Kent ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CONDYLOMA; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; NONHUMAN; REVIEW; SEROTYPE; SWELLING; SYSTEMATIC REVIEW; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION;

ADOLESCENT; ADULT; CARCINOMA IN SITU; CHILD; CONDYLOMATA ACUMINATA; CROSS INFECTION; DISEASE OUTBREAKS; EDEMA; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MALE; PAIN; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRACTICE GUIDELINES; SEXUALLY TRANSMITTED DISEASES, VIRAL; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VACCINATION; WORLD HEALTH;

EID: 33847119771     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Centers for Disease Control and Prevention. Genital HPV Infection - CDC Fact Sheet. Available at: http://www.cdc.gov/std/HPV/STDFact-HPV. htm. Accessed October 24, 2006.
2. American Cancer Society. Cancer Facts & Figures 2006. Available at: http://www.cancer.org/docrootySTT/content/ STT_1x_Cancer_Facts_Figures_2006.asp. Accessed October 24, 2006.
3. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151:1158-1171.
4. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
5. International Agency for Research on Cancer. Human Papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 64. Lyon, France: IARC Press; 1995:35-378.
6. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527.
7. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157;218-226.
8. US Department of Health and Human Services. Trends in the Well-Being of America's Children & Youth. Washington, DC: US Department of Health and Human Services; 2003.
9. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423-428.
10. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998;132:277-284.
11. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645-1651.
12. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia. Obstet Gynecol. 2006;107:18-27.
13. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10:1915-1923.
14. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a Human Papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604-615.
15. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. GlaxoSmithKline HPV Vaccine Study Group. Lancet. 2004;364:1757-1765.
16. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. HPV Vaccine Study Group. Lancet. 2006;367:1247-1255.
17. Sanders GD, Taira AV. Cost effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9:37-48.
18. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 5th ed. New York, NY: Oxford University Press; 2001.
19. Munson R. Intervention and Reflection: Basic issues in Medical Ethics. 7th ed. Belmont, Calif: Wadsworth/Thompson Learning; 2003.
20. Yacobi E, Tennant C, Ferrante J, Pal N, Roetzheim R. University students' knowledge and awareness of HPV. Prev Med. 1999;28:535-541.
21. Mays RM, Zimet GD, Winston Y, Kee R, Dickes J, Su L. Human papillomavirus, genital warts, pap smears, and cervical cancer: knowledge and beliefs of adolescent and adult women. Health Care Women Int. 2000;21:361-374.
22. Baer H, Allen S, Braun L. Knowledge of human papillomavirns infection among young adult men and women: implications for health education and research. J Community Health. 2000;25:67-78.
23. Holcomb B, Bailey JM, Crawford K, Ruffin MT IV. Adults' knowledge and behaviors related to human papillomavirus infection. J Am Board Fam Pract. 2004;17:26-31.
24. Ramirez JE, Ramos DM, Clayton L, Kanowitz S, Moscicki AB. Genital human papillomavirus infections: Knowledge, perception of risk, and actual risk in a nonclinic population of young women. J Womens Health. 1997;6:113-121.
25. Trauth JM, Zimmerman RK, Musa D, Mainzer HM, Nutini JF. Do beliefs of innercity parents about disease and vaccine risks affect immunization? J Natl Med Assoc. 2002;94:820-832.
26. Centers for Disease Control and Prevention. Vaccines for Children Program. Available at: http://www.cdc.gov/programs/immun10.htm. Accessed October 26, 2006.
27. Zimmerman RK. Ethical analysis of HPV vaccine policy options. Vaccine. 2006;24:4812-4820.
28. Centers for Disease Control and Prevention. ACIP provisional recommendations for use of quadrivalent HPV vaccine. August 14, 2006. Available at: http://www.cdc.gov/nip/recs/provisional_recs/hpv.pdf. Accessed October 26, 2006.